Online Purchasing Account You are logged on as Guest. LoginRegister a New AccountShopping cart (Empty)
United States 

IDO (human), (recombinant) (His-tag)

ALX-201-501-0050 50 µg 524.00 USD
Do you need bulk/larger quantities?

Product Specification

Alternative Name:Indoleamine 2,3-dioxygenase, INDO
Source:Produced in E. coli. Mature human IDO (indoleamine 2,3-dioxygenase) (aa 1-403) is fused at the C-terminus to a His-tag.
UniProt ID:P14902
Formulation:Liquid. 0.2µm-filtered solution in 50mM TRIS, pH 7.5, containing 100mM NaCl.
Purity:≥95% (SDS-PAGE)
Endotoxin Content:<1.0EU/µg protein (LAL test; Bio Whittaker).
Specific Activity:> 200 U/μg.  One unit is defined as the conversion  of 1 pmol/min L-tryptophan to N-formylkynurenine.
Activity assay
Application Notes:Western blot control.
Shipping:Shipped on Dry Ice
Long Term Storage:-80°C
Use/Stability:Working aliquots are stable for up to 12 months when stored at -80°C.
Handling:Avoid freeze/thaw cycles. After opening, prepare aliquots and store at -80°C.
Scientific Background:Indoleamine 2,3-dioxygenase (IDO) is an enzyme that catalyzes the degradation of L-tryptophan to N-formylkynurenine. This immunomodulatory enzyme has been shown to allow tumor cells to escape the immune system by depletion of L-Trp in the microenvironment of cell A wide range of human cancers overexpress human IDO (hIDO).
ALX-201-501 SDS-PAGE
SDS-PAGE analysis - Lane 1: MW Marker, Lane 2: 1 μg IDO. (Prod. No. ALX-201-501, IDO (human), (recombinant) (His-tag))
ALX-201-501 WB
Western blot analysis – Lane 1: MW Marker, Lane 2: 100 ng IDO. Probed with pAb raised against full-length human recombinant IDO. (Prod. No. ALX-201-501, IDO (human), (recombinant) (His-tag)).
Please mouse over
ALX-201-501 SDS-PAGE ALX-201-501 WB

Product Toolbox


Certificate of Analysis


By target:
By biological activity:
IDO Recombinant protein
By catalog section:


Technical Service
Customer Service

Recommend this page

For Research Use Only. Not for use in diagnostic procedures.
Keep in touch

©2018 Enzo Life Sciences, Inc.,